All Eyes on Valeant Pharma (VRX) EBITDA, Which is Expected to be Lowered - Evecore ISI's Raffat

August 8, 2016 1:57 PM EDT
Get Alerts VRX Hot Sheet
Price: $21.96 -0.45%

Rating Summary:
    12 Buy, 11 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade VRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Valeant Pharma (NYSE: VRX) analyst Umer Raffat from Evecore ISI weighed in ahead of tomorrow's all-important second quarter report. He said by and far the key will be EBITDA.

He notes current 2016 EBTIDA guidance is $4.8 - $4.95B. Further he notes that ~75% investors in his recent buyside survey expected Valeant to lower 2016 EBITDA.

For Q2 EBITDA, the consensus is ~$1.1B.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Hot Comments, Trader Talk

Related Entities

Umer Raffat

Add Your Comment